Pressure for increased transparency in pharma can create antitrust risks, says Novartis counsel

The wealth of information available about pharmaceutical prices presents antitrust risks in the current political environment, a Novartis in-house lawyer said yesterday.

Get unlimited access to all Global Competition Review content